A Phase 4 interventional study of Paracetamol and Caffeine and Paracetamol in Common Cold, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-25.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Common Cold with a site in United Kingdom — none open to participants now, 1 under way, none of them phase 3. Common Cold · United Kingdom.
Among the 20 studies in Common Cold with a site in United Kingdom, this one is the 12th largest by enrollment, is one of 3 that started in 2011, is one of 5 in phase 4, and was the 7th registered.
219 studies on the registry are indexed under Common Cold; 23 are open to participants now.
Browse Common Cold studies →None of the 20 studies in Common Cold with a site in United Kingdom is open now. The open studies under Common Cold, anywhere →
Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is below the median of 150 across 184 interventional studies indexed under Common Cold.
Median enrollment 89 across the 20 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 20 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 9 studies filed under Common Cold — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Common Cold with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A reduction in alertness and lower levels of performance are commonly associated with the common cold. Paracetamol has been shown to be more effective than placebo in treating symptoms associated with upper respiratory tract infection; caffeine has been shown to increase levels of alertness and improve performance of people suffering from colds. This study will investigate any improvement in alertness and performance based on cognitive function and mood assessment in subjects suffering from the common cold, when taking a novel paracetamol and caffeine combination verses paracetamol alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paracetamol and caffeine
Drug: Paracetamol and Caffeine
Paracetamol
Drug: Paracetamol
Drug pages: Acetaminophen · Caffeine
Paracetamol 1000 mg and caffeine 130 mg
Paracetamol 1000 mg
Adjusted Mean Change From Baseline in Number of Valid Responses to Rapid Visual Information Processing (RVIP) Cognitive Test
The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated.
Time frame: Baseline to 30 minutes post treatment administration
Adjusted Mean Change From Baseline in Number of Valid Responses to RVIP Cognitive Test
The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated.
Time frame: Baseline to 60 minutes post treatment administration
Adjusted Mean Change in Baseline in Valid Reaction Time to RVIP Cognitive Test
The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. Mean valid reaction time was determined.
Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration
Mean Change From Baseline in Number of Incorrect and Missed Responses to RVIP Cognitive Test
The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated.
Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration
Adjusted Mean Change From Baseline in Number of Valid Responses to Sustained Attention Tasks (SAT) Cognitive Test
Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of valid responses to visual and auditory tests were calculated.
Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration
Mean Change From Baseline in Number of Incorrect and Missed Responses to SAT Cognitive Test
Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of incorrect and missed responses to visual and auditory tests were calculated.
Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration
Adjusted Mean Change From Baseline in Valid Reaction Time to SAT Cognitive Test
Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of valid reaction time to visual and auditory tests were calculated.
Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration
Adjusted Mean Change From Baseline in Number of Valid Responses to Divided Attention Task (DAT) Cognitive Test
For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of valid responses to visual and auditory tests were calculated.
Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration
Adjusted Mean Change From Baseline in Valid Reaction Time to DAT Cognitive Test
For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of valid reaction time to visual and auditory tests were calculated.
Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration
Mean Change From Baseline in Number of Incorrect and Missed Responses to DAT Cognitive Test
For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of incorrect and missed responses to visual and auditory tests were calculated.
Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration
Adjusted Mean Change From Baseline in Mood Alertness and Physical Sensation Scales (MAPSS) Cognitive Test
Mood patterns was evaluated using the Mood, Alertness and Physical Sensation Scales (MAPSS) which comprised of 23 questions describing moods and physical sensations, on a 9-point scale anchored at the left hand end with 'not at all' and the right hand end with 'extremely'. For each question, '9' represented the 'best' score and '1' represented the 'worst' score. Mean score was calculated by summing the responses and dividing by the number of questions answered. MAPSS Questionnaire was further divided into three main clusters: Alertness; Anxiety and Headache as per the questions.
Time frame: Baseline, 30 minutes and up to 60 minutes post treatment administration
Participants were recruited at the clinical site.
| Milestone | Paracetamol/ Caffeine Tablet Then Paracetamol Powder | Paracetamol Powder Then Paracetamol/ Caffeine Tablet |
|---|---|---|
| Started | 36 | 36 |
| Intent to treat (itt) population | 36 | 35 |
| Completed | 36 | 35 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Paracetamol/ Caffeine Tablet Then Paracetamol Powder | Paracetamol Powder Then Paracetamol/ Caffeine Tablet |
|---|---|---|
| Started | 35 | 36 |
| Completed | 35 | 36 |
| Not completed | 0 | 0 |
The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated.
| Valid responses | Paracetamol/ Caffeine Tablet | Paracetamol Powder |
|---|---|---|
| Adjusted Mean Change From Baseline in Number of Valid Responses to Rapid Visual Information Processing (RVIP) Cognitive Test | 4.8 ± 0.80 | 1.3 ± 0.80 |
The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated.
| Valid responses | Paracetamol/ Caffeine Tablet | Paracetamol Powder |
|---|---|---|
| Adjusted Mean Change From Baseline in Number of Valid Responses to RVIP Cognitive Test | 7.1 ± 0.93 | 0.6 ± 0.93 |
The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. Mean valid reaction time was determined.
| milliseconds (msec) | Paracetamol/ Caffeine Tablet | Paracetamol Powder |
|---|---|---|
| 30 minutes | 6.00 ± 3.916 | 1.88 ± 3.916 |
| 60 minutes | 0.08 ± 3.983 | -4.85 ± 3.954 |
The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated.
| Responses | Paracetamol/ Caffeine Tablet | Paracetamol Powder |
|---|---|---|
| Incorrect responses at 30 minutes | -2.3 ± 1.57 | -2.7 ± 1.52 |
| Incorrect responses at 60 minutes | -1.7 ± 1.93 | -2.7 ± 1.80 |
| Missed responses at 30 minutes | -4.8 ± 0.69 | -1.3 ± 0.89 |
| Missed responses at 60 minutes | -7.1 ± 0.90 | -0.6 ± 1.00 |
Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of valid responses to visual and auditory tests were calculated.
| Valid responses | Paracetamol/ Caffeine Tablet | Paracetamol Powder |
|---|---|---|
| 30 minutes | 1.8 ± 0.52 | -0.5 ± 0.51 |
| 60 minutes | 1.5 ± 0.55 | -0.7 ± 0.55 |
Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of incorrect and missed responses to visual and auditory tests were calculated.
| Responses | Paracetamol/Caffeine Tablet | Paracetamol Powder |
|---|---|---|
| Incorrect responses at 30 minutes | -2.3 ± 0.63 | 0.1 ± 0.65 |
| Incorrect responses at 60 minutes | -3.6 ± 0.71 | 0.6 ± 0.72 |
| Missed responses at 30 minutes | -1.8 ± 0.59 | 0.5 ± 0.44 |
| Missed responses at 60 minutes | -1.5 ± 0.54 | 0.7 ± 0.55 |
Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of valid reaction time to visual and auditory tests were calculated.
| msec | Paracetamol/ Caffeine Tablet | Paracetamol Powder |
|---|---|---|
| 30 minutes | -6.49 ± 2.80 | -6.18 ± 2.75 |
| 60 minutes | -10.69 ± 3.12 | -9.45 ± 3.10 |
For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of valid responses to visual and auditory tests were calculated.
| Valid responses | Paracetamol/ Caffeine Tablet | Paracetamol Powder |
|---|---|---|
| 30 minutes | 6.8 ± 1.00 | 2.0 ± 0.99 |
| 60 minutes | 7.4 ± 1.01 | 1.9 ± 1.00 |
For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of valid reaction time to visual and auditory tests were calculated.
| msec | Paracetamol/ Caffeine Tablet | Paracetamol Powder |
|---|---|---|
| 30 Minutes | 1.65 ± 2.10 | -7.42 ± 2.07 |
| 60 minutes | -5.49 ± 2.44 | -12.39 ± 2.43 |
For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of incorrect and missed responses to visual and auditory tests were calculated.
| Responses | Paracetamol/Caffeine Tablet | Paracetamol Powder |
|---|---|---|
| Incorrect responses at 30 minutes | -5.4 ± 0.83 | -1.4 ± 0.83 |
| Incorrect responses at 60 minutes | -5.2 ± 0.77 | -0.2 ± 0.92 |
| Missed responses at 30 minutes | -6.7 ± 1.19 | -2.0 ± 0.83 |
| Missed responses at 60 minutes | -7.4 ± 1.24 | -1.9 ± 0.75 |
Mood patterns was evaluated using the Mood, Alertness and Physical Sensation Scales (MAPSS) which comprised of 23 questions describing moods and physical sensations, on a 9-point scale anchored at the left hand end with 'not at all' and the right hand end with 'extremely'. For each question, '9' represented the 'best' score and '1' represented the 'worst' score. Mean score was calculated by summing the responses and dividing by the number of questions answered. MAPSS Questionnaire was further divided into three main clusters: Alertness; Anxiety and Headache as per the questions.
| Score on a scale | Paracetamol/Caffeine Tablet | Paracetamol Powder |
|---|---|---|
| Alertness at 30 minutes | 0.8 ± 0.12 | 0.2 ± 0.12 |
| Alertness at 60 minutes | 0.7 ± 0.13 | 0.1 ± 0.13 |
| Anxiety at 30 minutes | 0.2 ± 0.08 | 0.2 ± 0.08 |
| Anxiety at 60 minutes | 0.3 ± 0.08 | 0.4 ± 0.08 |
| Headache at 30 minutes | 0.4 ± 0.10 | 0.4 ± 0.10 |
| Headache at 60 minutes | 0.6 ± 0.10 | 0.6 ± 0.10 |
Collected over Adverse Events were collected from the start of the investigational product and until 5 days following last administration of the investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paracetamol/Caffeine Tablet | — | 0/71 (0%) | 0/71 (0%) |
| Paracetamol Powder | — | 0/71 (0%) | 0/71 (0%) |
| Age Continuous(Years) | All Randomized Participants |
|---|---|
| Mean | 20.8 ± 4.19 |
| Sex: Female, Male(Participants) | All Randomized Participants |
|---|---|
| Female | 47 |
| Male | 24 |
The record gives a start of Feb 2011, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetaminophen · Caffeine